Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

The RSClinN+ tool integrates the 21-gene Recurrence Score with clinicopathological factors to predict prognosis and chemotherapy benefit in both pre- and postmenopausal patients with HR+ HER2- node-positive breast cancer by estimating 5-year invasive disease-free survival rates with endocrine therapy alone versus chemo-endocrine therapy. The tool was developed from data from more than 5,000 patients in the S1007 and S8814 trials and validated in an external registry. Compared with the 21-gene Oncotype DX Breast Recurrence Score or clinical factors alone, RSClinN+ provided improved estimates of prognosis and absolute chemoendocrine therapy benefit for individual patients.